Introduction
The prevalence of epilepsy in adults with an intellectual disability (ID) is up to 20 times greater than in the general population [1] . A recent survey of carers and professionals showed considerable concern over presence and impact of side effects from anti-epileptic drug (AED) treatment in people with ID (in particular drowsiness, memory problems, depression) [2] . The term side effect typically relates to any secondary undesirable effect of a treatment or drug. Physical, cognitive, behavioural or emotional side effects can cause significant impact on the quality of life of an individual. Monitoring side effects in adults with ID and epilepsy is challenging due to the commonly co-existing occurrence of behaviour and communication disorders [3] . The incidence of side effects is estimated to be as high as 58% in the wider population receiving treatment (i.e. adults with epilepsy without ID) [4] . Javed noted that patients with ID were less likely to report side effects than patients without ID, especially in regard to cognitive adverse events [5] . A recent Cochrane review concluded that side effects in the ID population are similar to the general population, however the authors note that this is concluded from limited studies with unreliable measures [6] .
The importance of Patient Reported Outcome Measures (PROMs) in assessing health status is increasingly acknowledged, both in research and in the evaluation of routine clinical care. In a report published in 2009 [7] , the Medical Research Council (MRC) suggest several key areas for future research, including addressing gaps in currently available PROMs, such as for use at end of life and in children. However, the gap in available PROMs for use with adult ID populations and their families/carers would seem to be greater still. Screening tools are available to assess AED side effects in the general adult population, and research suggests that active monitoring is sufficient to change management and improve quality of life (QoL) [8] . It is not known however whether such tools can be used to identify side effects in adults with ID, or whether included items are important and relevant to patients and carers. The importance of developing PROMs that are reliable, valid and sensitive to change within the context of clinical trials has also been highlighted [9] and specification, selection and measurement of appropriate outcomes is central to all stages of the MRC guidance on complex intervention development [10] . However, a Cochrane review concluded that the measurement of side effects in this population was hampered by reliability of available measures [11] . In addition those with ID (and individuals with low literacy levels) are often excluded from the PROMs development process [9] . Therefore measures may not be accessible or acceptable to this population and are likely therefore to produce unreliable data if Side effect outcome measures as stated in the methods section of the paper included, but were not limited to the following domains: seizure severity/frequency; psychiatric symptoms; social function; cognitive functioning; challenging behaviour; mood; quality of life; physical symptoms.
Studies were excluded if the seizure disorder occurred as a side effect of medical treatment or was not specified as epilepsy. Papers were excluded where no outcome data had been published. Papers reported from on-going studies which may be relevant (e.g. some feasibility/qualitative investigation of side effects which then informed outcome assessment) were included. For the full list of search terms see Appendix A. 
Information sources

Search strategy
Appropriate keywords were used e.g: epilepsy, anti-epileptic drug, anticonvulsants, outcome measures/ment, scales, side effects, tolerability, seizure severity and frequency, psychiatric, cognition challenging behaviour, mood and quality of life (for details of the full search strategy see Appendix A). Each search term was classified under one of 4 categories: participants, medication, measures and side effect domains, which were combined (requiring all four domains to be included) in the database searches.
Data collection
Identified papers (n = 462) were assessed independently by two researchers and checked for eligibility of abstract and title according to the inclusion and exclusion criteria (see Appendix A). Studies that met inclusion criteria (n = 153) were obtained in full text and again checked for eligibility against the same criteria by one researcher. 40% were double checked independently for eligibility by a second researcher. Any disagreements identified were reviewed by both researchers and discussed to resolve differences. 95 eligible papers were included in the review.
Data extraction
A data extraction spreadsheet was created based on the research question. The data extraction fields included recruitment data, epilepsy and ID diagnosis, outcome measure and who completed the measure. The data extraction sheet was piloted and minor amendments made prior to being finalised.
Data synthesis
Each paper was summarised descriptively in terms of AED type, side effect domain, AED/QoL measures and who rated the measure (i.e. patient, carer/professional, proxy). Due to the nature of the review aim, it was not possible to carry out a meta-analysis and a narrative synthesis was performed instead to summarize the outcome measures. Narrative synthesis is a systematic review and synthesis of multiple studies that is summarized in text format. The review had originally aimed to include a meta-analysis looking at associations between side effects and other important outcomes e.g. psychological well-being and challenging behaviour however no such data were reported.
Results
The initial search via electronic databases yielded 494 records and an additional 36 records were identified through hand searching. Subsequent removal of duplicates resulted in 462 papers remaining (see Fig. 1 ). Following independent review by two researchers of the abstracts according to the inclusion and exclusion criteria 153 studies were included for full paper review. From this selection 95 studies were identified as suitable for inclusion for the purposes of review.
3.1. Summary of studies by side effect domain and measure in general and ID adult epilepsy populations Table 1 presents a summary of studies by side effect domain and measure. The side effects measured by the studies range from adverse events, behavioural and cognitive changes, through to sexual functioning and quality of life. There are 108 measures used across all the studies. Eleven of these measures were used in the ID studies. Of the 108 measures, eight are designed for use with people with ID. The majority (51) of the measures for the general adult population were to be rated by the participant. This is in contrast to the measures used in the ID studies which were carerrated.
Summary of studies with a focus on intellectual disability
Within the 95 papers identified as suitable for inclusion, the reviewers found eight studies that looked at adults with epilepsy Negative side effects were reported more often in patients with ID than in general adult population patients.
The type of epilepsy was not specified.
Barratt Impulsiveness Scale-11: BIS-11
Behavioral changes across the sample while taking LEV (12% very negative, 25% negative, 16% positive, and 6% very positive) 14 participants were described as being 'mentally retarded' with 5% being in the LEV group and 14% in the control group A moderate to severe ID (ICD-10 classification: F71, 38%; F72, 52%).
Aberrant Behavior Checklist (ABC).
McKee et al. [36] Patients aged at least 12 years of age.
Lamotrigine
Percentage of patients with reductions in seizure frequency.
Majority improvements in seizure frequency, duration and intensity. An intellectual disability based on Diagnostic and Statistical Manual IV (DSM-IV) criteria. More than two-thirds were severely or profoundly 'mentally retarded'.
Habilitative Improvement Scale.
Adverse events
No change found relative to baseline for most patients with regards to intellectual and motor functioning.
Mean ABC scores for lethargy and stereotopy showed significant improvement,
Mean Habilitative Improvement Scale scores showed significant improvement.
Adverse events were reported in at least 5% of patients and included somnolence, dizziness, ataxia and emotional change.
McKee et al. [37] Patients aged 12 to 20 years. Lamotrigine Aberrant Behaviour Checklist 60% of participants noted a 50% reduction in seizure frequency, 45% reported a 75% reduction, and 25% of participants reported zero seizures.
Refractory epilepsy.
Habilitative Improvement Scale The mean score on the Habilitative Improvement Scale improved significantly from baseline.
An intellectual disability classifiable by the DSM-IV criteria. 64% had a classification of severe or profound 'mental retardation'.
Adverse events and seizure counts were recorded by caregivers throughout the study.
Improvements in all 5 subdomain areas of the Aberrant Behavior Checklist.
80% of participants did not experience any clinically relevant change in adverse effects.
Dizziness, somnolence, and abdominal pain were infrequently reported. Vomiting was the most common adverse event. Mild, moderate, severe or profound 'mental retardation' based on DSM IV criteria.
Seizure counts by type of seizure were recorded by caregivers.
The mean Habilitative Improvement Scale scores reflected improved functioning amongst the community based participants however the mean score was significantly improved in relation to the baseline phase for both groups of participants.
Adverse events recorded by caregivers.
Lethargy, stereotypy, hyperactivity and inappropriate speech ABC domain scores were found to be significantly improved for the community based group.
No differences were found in any ABC domains for the group residing in institutional settings.
Behavioural and functionality domains
Crawford et al. [40] Participants aged 12 years and over
Gabapentin and Lamotrigine Key Carer-rated Visual Analogue Scales
The results showed no difference between groups on the Visual Analogue Scales;
Participants were diagnosed with localisation-related epilepsy.
Whelan and Speake Rating Scale Both drugs seemed to reduce challenging behaviour as rated by Whelan and Speake Rating Scale.
An intellectual disability and met the DSM-IV criteria for 'mental retardation' on a range of levels.
Crichton Royal Behavioural Rating Scale
Functionally improved significantly with gabapentin compared to lamotrigine as rated by the Crichton Royal Behavioural Rating Scale.
Physician's Global Rating Scale. The Physician's Global Rating Scale showed statistically significant improvements over baseline (P < 0.01) for challenging behaviour, seizure severity and general health for both treatment groups. [40] looked at behaviour as well as functionality and one paper examined cognitive adverse events [48] . The final paper [12] examined both functionality and quality of life. Table 2 summarizes studies identified which have a focus on intellectual disability. All of the above studies investigate the effectiveness of specific AED drugs on participants with epilepsy and ID. The studies report the efficacy of the AED and any side effects. Several AEDs are examined and there are a mixture of results in terms of efficacy and side effects. Some of the studies report improvements within side effect domains [16] [17] [18] 20] , whilst other studies showed no or little improvement [35, 82, 85] .
The studies use the various measures to investigate behaviour, functionality, cognitive and quality of life domains, however, studies also recorded adverse events. One study [35] reported 57 treatment-emergent adverse events (TEAEs) in 21 of the 29 patients from a safety cohort (72.4%) during treatment. Gastrointestinal disorders and nervousness/restlessness (4 of 29 safety set patients) and tiredness/sedation/adynamia, ear/nose/throat infections, injuries, and mental state disorders (3 patients each) were the adverse effects captured most frequently [35] . Further studies [12, [36] [37] [38] , also reported adverse events deemed to be drugrelated including somnolence, dizziness, ataxia, emotional change and vomiting. Therefore although there are a number of measures which focus on side effects it is also noted that adverse event recording is an alternative way of capturing information about side effects as opposed to using specific outcome measures.
Helmstaedter et al. [85] suggest that patients with ID reported negative side effects more often than patients with normal development. This highlights the need for a measure of AED side effects for those with ID. According to the authors of the other studies [35] [36] [37] [38] identified in this review, ABC, MESSIER and Habilitative Improvement Scale scores are sensitive to change. Crawford et al. [40] stated that although they found no difference between the groups in their study for challenging behaviour, functioning did improve significantly with Gabapentin compared to Lamotrigine. Both groups showed statistically significant improvements over baseline (P < 0.01) for challenging behaviour, seizure severity and general health. The same study also found no significant change in reported behaviour between the Topiramte and placebo groups, using a specific behaviour change measure. Concurrently the quality of life measures did not indicate any significant decline in quality of life. From these results there appear to be no significant side effects from the intervention AEDs, although this may reflect the choice of measure or proxyassessment, rather than the absence of any negative effects.
Side effects and adverse events were assessed within each study using variable methods. For example Crawford et al. [40] recorded seizure occurrences in diaries and safety and tolerability were assessed by adverse event reports, however it is not noted who completed these diaries or reports (i.e. if they were completed by the participant or the carer). Minimal details regarding method of recording adverse events and seizure occurrence are included within the method sections of these papers. For example, Sunder et al. [38] notes that adverse events and seizure occurrence were recorded by caregivers however no further details are available on the formats used to collect this data. There were no studies which included self-reported measures of seizure occurrence or adverse/ side effects.
The functionality domain measures included in this review were the Adaptive Behaviour Scale (ABS-R) [99] , the Habilitative Improvement Scale [100] and the Crichton Royal Behavioural Rating Scale [101] . The ABS-R and Habilitative Improvement Scale were again carer rated, in the studies reported. The Habilitative Improvement Scale and Crichton Royal Behavioural Rating Scale are recommended for carer-completion, possibly to provide a more objective assessment of functionality. With the exception of the Adaptive Behaviour Scale these measures have not been developed to measure functionality in patients with ID.
The final side effect domains noted in these studies were quality of life and cognitive adverse events. In relation to cognitive changes Brandt [48] strongly recommended that these adverse events are assessed during the course of treatment, and that the effective assessment of adverse events in people with epilepsy is essential as the occurrence of such events has an impact on a persons' quality of life, in patients who are able to follow the instructions established neuropsychological instruments may be used. Quality of Life was measured using the Epilepsy and Learning Disabilities Quality of Life (ELDQoL) [102] measure and the Epilepsy Outcome Scale [103] . Both of these measures were developed specifically for people with ID to be rated by their carer. Although it is positive these measures were developed for the ID population they do not gather the data from the ID patient themselves leading to proxy quality of life scores. Table 3 outlines side effect measures identified within included studies. The outcome measures identified with a focus on behaviour as a side effect domain included Key Carer-rated Visual Analogue Scales [20] , Matson Evaluation of Social Skills in Individuals with Severe Retardation (MESSIER) [104] , Aberrant Behavior Checklist (ABC) [105] , Barratt Impulsiveness Scale-11 (BIS-11) [106] , Fragebogens zur Persönlichkeit bei zerebralen Erkrankungen (FPZ) and the Whelan and Speake Rating Scale [107] . All these measures apart from the Key Carer-rated Visual Analogue Scale and the Barratt Impulsiveness Scale-11 (BIS-11), were carerrated in the reported studies. The BIS-11, FPZ and Whelan and Speake Rating Scale were not developed for use in ID populations and therefore may not take account of the potential differences in behavioural side effects experienced in ID and general adult and elderly epilepsy populations [6] .
Measures of side effects
Discussion
We chose to undertake a review of the measurement and impact of AED side effects in general and adult intellectual disability populations, with a particular focus on results relating to identifying side effect measures of AED use (e.g. adaptive functioning, cognitive symptoms) either specifically designed for use in ID populations, or that could be adapted for this purpose. We identified 95 eligible papers, eight of which [12, [35] [36] [37] [38] 40, 48, 82] , focused specifically on ID populations. The side effects measured by the studies range from adverse events, behavioural and cognitive, through to sexual function and quality of life. The majority of the measures for the general adult population were to be rated by the participant. This is in contrast to the measures used in the ID studies which were carer-rated. These findings replicate those of Townsend et al. who undertook a systematic review of quality of life measures for people with intellectual disabilities and challenging behaviours, reporting that the number of subjective (self-reported) quality of life measures appropriate for use by people with intellectual disabilities is limited [109] . Outcome measures identified in this review can be broadly categorised within the following side effect domains; behaviour, impulsiveness, functionality, cognitive and quality of life.
The measures identified in this review do not typically contain sufficient and appropriate content to identify changes in the overall side effects of AED's in ID populations. They are generally by-proxy measures of behavior or mood change, and as such lack face and content validity in the context of drug effects. Reliability and validity of the identified measures are not therefore reported in this paper.
The term side effect is defined as: "Any unwanted nontherapeutic effect caused by a drug" [110] . Adverse events are defined in Article 2(m) of Directive 2001/20/EC as: "Any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment" [111] .
In the papers identified in this review, the terms "side effect" and "adverse events" are used interchangeably throughout. Such side effects or adverse events are seldom focused on in the same way and cover a wide range of impacts, for example on adaptive or challenging behaviour or quality of life. Side effects and adverse events are generally measured in an ad hoc manner, with no standardised way of recording type or frequency of occurrence. In the majority of cases, events are carer-reported or the responder is unspecified. Given the methodology otherwise reported, particularly if diaries or standardised measures are used, it is likely that assessments are made by carers if not otherwise specified.
Studies have also included adverse events reported by participants to the clinician or researcher. Furthermore, these adverse events are not explicitly addressed by the outcome measures used by the included studies within this review. As the treatment-emergent adverse events referred to above were reported voluntarily by participants, these may represent side effects that they were particularly concerned about, were severe or that occurred most frequently.
Thompson [2] undertook a qualitative study of carer and professional views on the management of people with intellectual disability and epilepsy and found that respondents noted a number of side effects, but that the impact of these side effects was not well understood by clinicians, who in some cases demonstrated a lack of empathy with patients and families. One family member noted that including the patient in discussions helps:
"I sometimes feel that a percentage of people taking AEDs would be, on the whole, better off without them. Side-effects are often passed off as being unimportant and the recommendation generally is to continue increasing a drug. Listening to the patient helps" [2] .
Kerr states that it is important to recognise that the majority of patients in this population are unable to self-report side effects and Crawford et al. [40] a Scale developed specifically for study. b Out of print.
as such there is a tendency for only the more overt side effects (such as vomiting or weight gain) to come to the attention of the clinician [3] . Our findings suggest that side effects of AEDs are inconsistently and inadequately measured in ID populations, and as such are likely to be under-reported. This is consistent with a broader debate reported in the literature focusing on the absence of the patients' voice in drug trials. The adverse events that are reported during drugs trials are almost entirely clinicians' impressions of patients symptoms rather than the patients report [112] . Further to this issue a recent review [113] has found the clinician reporting of adverse events provides complementary information to patient reported outcome measures. Integration of these two measures could improve clinicians and policy makers interpretations of clinical trials. It is not known whether currently available PROMs used in the general adult population can be used to identify side effects in adults with ID, or whether the items included in existing measures are important and relevant to this group of patients and their carers. Furthermore, one of the two outcome measures identified that is designed for an ID population, is intended to be rated by carers, and focuses on the more theoretical concept of quality of life (which in practice may be poorly defined) rather than on side effects of medication per se.
The results of the current review would seem to support the assertion that patients themselves may not be as involved in discussion as they should be, and that outcome measures developed specifically for use in adults with epilepsy and ID are either not available or not commonly used. Furthermore, clinicians and researchers alike appear to have a preference for using proxy rather than patient assessment. However, this may be due to availability of suitable measures.
There are several limitations within this review. In one study [85] only 14 out of 331 participants were reported to have had an intellectual disability. However this was taken from patient files and not from psychometric evaluations, so the real figure may have been different. Due to these low numbers the study may have used different measures more appropriate for the general population rather than the ID population. A further limitation of the review is that the grey literature was not searched.
The low numbers of studies identified relating specifically to the ID population shows there is a clear need for further research in this field. It should also be noted that although the majority of measures were not developed specifically for the ID patient population they may nevertheless be useful instruments within the clinical setting. Measures are frequently used for research/ evaluation purposes and so further investigation would be helpful in identifying why such measures are not utilized in the clinical environment.
Conclusion
Measurement tools are available to assess AED side effects in the general adult population, however as demonstrated by this review there are limited outcome measures designed specifically to be used in ID populations. Furthermore, the focus of these measures is broader than side effects alone, and as such they may not be sufficiently in-depth to pick up the full range of side effects of importance in this group.
Research suggests that active monitoring of AED side effects in the general adult population is sufficient to change management and improve quality of life (QoL) [8] . Therefore, there is a need for measures developed specifically to address the potentially different impact of these medications in patients with ID. Given the high level of comorbidities such as Autistic Spectrum Disorder or mental health issues and concomitant medication use these are factors which also need to be considered within the ID population when examining the side effects of AED medication. Within this study there were no measures identified which focused on populations of people with Autism. With regards to AED side effects in the ID population Kerr (2009) recommended within international consensus guidelines, that baseline cognitive and behavioural assessments should be made and then re-measured after drug changes, with validated measures preferred [3] . There is a lack of established and validated assessment scales for patients with ID and epilepsy, but the fact that this is a heterogenous population and there is a wide range of diversity in communication and cognitive deficits, mean it is challenging to develop a scale or measure that is suitable for all. Thornicroft and Tansella [114] suggest that important properties for patient based outcome measures are feasibility, appropriateness, reliability, validity, responsiveness, precision, interpretability and, acceptability. In ID populations, several additional factors should also be considered in order for the measure to be truly patient reported such as adaptability for capacity, accessibility and length/completion time, to facilitate use in a busy clinical setting. Nevertheless there is a clear need to develop a psychometrically sound measure that allows patients with epilepsy and ID to self-report the side effects of their AED medication as far as is possible.
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Methods
A search strategy was developed for electronic databases on Ovid Medline using both keywords and MeSH headings. The developed search strategy is below. The named anti-epileptic drugs were chosen in consultation with medical professionals. The search strategy was modified to search the rest of the databases. To be eligible, studies would need to include: Adults AND epilepsy (but we want to identify sub-set with LD/ ID) AND medication AND side effects AND scale/outcome measure.
